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PURPOSE: Hypomelanosis of Ito (HI) is a skin marker of somatic mosaicism. Mosaic MTOR pathogenic variants have been reported
in HI with brain overgrowth. We sought to delineate further the pigmentary skin phenotype and clinical spectrum of
neurodevelopmental manifestations of MTOR-related HI.
METHODS: From two cohorts totaling 71 patients with pigmentary mosaicism, we identified 14 patients with Blaschko-linear and
one with flag-like pigmentation abnormalities, psychomotor impairment or seizures, and a postzygotic MTOR variant in skin. Patient
records, including brain magnetic resonance image (MRI) were reviewed. Immunostaining (n= 3) for melanocyte markers and
ultrastructural studies (n= 2) were performed on skin biopsies.
RESULTS: MTOR variants were present in skin, but absent from blood in half of cases. In a patient (p.[Glu2419Lys] variant),
phosphorylation of p70S6K was constitutively increased. In hypopigmented skin of two patients, we found a decrease in stage 4
melanosomes in melanocytes and keratinocytes. Most patients (80%) had macrocephaly or (hemi)megalencephaly on MRI.
CONCLUSION: MTOR-related HI is a recognizable neurocutaneous phenotype of patterned dyspigmentation, epilepsy, intellectual
deficiency, and brain overgrowth, and a distinct subtype of hypomelanosis related to somatic mosaicism. Hypopigmentation may
be due to a defect in melanogenesis, through mTORC1 activation, similar to hypochromic patches in tuberous sclerosis complex.
Genetics in Medicine (2021) 23:1484–1491; https://doi.org/10.1038/s41436-021-01161-6
INTRODUCTION
Hypopigmentation along Blaschko’s lines defines hypomelanosis
of Ito (HI). Although in the initial description1 extracutaneous
findings were not reported, HI was later recognized as a
neurocutaneous disorder because of the frequency of brain
involvement and epilepsy.2–4 Hemihypertrophy and additional
developmental anomalies also appear to be more common in
HI.5,6 In some patients, it may be difficult to determine whether
the affected skin is hypopigmented or hyperpigmented,7 hence
the name “pigmentary mosaicism,” encompassing both types of
linear dyschromia.8 For hypopigmentation, the denominations
“pigmentary mosaicism of the Ito type” or “linear hypomelanosis
in narrow bands” have also been suggested.9
The genetic basis of HI is only partially understood. It has long
been recognized as a hallmark of somatic mosaicism, since
multiple nonrecurrent mosaic chromosomal anomalies have been
reported in patients with this clinical feature.10,11 In contrast to
chromosomal anomalies however, few mosaic single-gene
anomalies have been reported in pigmentary mosaicism so far.
In rare cases, mosaic activating MTOR pathogenic variants have
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been detected in the brain, blood, or buccal swabs (Supplemen-
tary Table 1), but in most patients, genetic testing was not
performed on skin biopsy, and their functional consequences on
skin pigmentation were not studied.
Besides somatic mosaic MTOR pathogenic variants in brain
tissue, germline MTOR pathogenic variants have been reported in
patients with Smith–Kingsmore syndrome (OMIM 616638) (Sup-
plementary Figure 1), which consists of intellectual disability with
macrocephaly, ventriculomegaly, seizures, and facial dysmorphism
(midface hypoplasia, hypertelorism, downslanted palpebral fis-
sures, depressed nasal bridge, thin upper lip, flat philtrum).
To characterize hypomelanosis of Ito with neurodevelopment
anomalies related to MTOR variants clinically and genetically, we
performed in-depth phenotyping in HI patients harboring mosaic
MTOR pathogenic variants in the skin, including brain magnetic
resonance imaging (MRI) and microscopic and ultrastructural skin
analysis. We now provide further delineation of the cutaneous and




Patients were ascertained by clinical geneticists or dermatologists in ten
French centers (Dijon, Lille, Montpellier, Créteil, Paris-Trousseau, Rennes,
Clermont-Ferrand, Reims, Paris-Robert-Debré, La Réunion), as part of a
nationwide collaborative effort for identification of genes involved in
cutaneous mosaic syndromes. Inclusion in the cohort required presence of
both cutaneous and extracutaneous manifestations. Inclusion criteria in
the phenotype study consisted of skin or hair hypopigmentation in a
mosaic pattern—linear, segmental, or flag-like—associated with any type
of extracutaneous involvement, and presence of a postzygotic MTOR
variant. Criteria of noninclusion were diagnoses of Mendelian disorders of
pigmentation, particularly Waardenburg syndrome and piebaldism, or
hypochromic bands resulting from linear inflammatory conditions, such as
lichen striatus or inflammatory linear verrucous epidermal nevus (ILVEN).
All clinical features were recorded on a clinical research form, and
cutaneous images were centralized and reviewed at the coordination
center by two experts (A.S., P.V.). Cerebral MRI was performed at each
center and centralized reading was performed by three other experts (C.M.,
D.R., L.G.).
Next-generation sequencing
DNA analysis was performed at Dijon GAD laboratory, Université de
Bourgogne, for 13 patients, and at University College London for 2
patients. Genomic DNA was extracted from blood, 5-mm punch biopsies of
hypopigmented skin, cultured skin fibroblasts, buccal swabs, and saliva
specimens. Details on next-generation sequencing are available in Supple-
mentary Methods.
In-depth exome sequencing on whole-skin biopsies and blood genomic
DNA was initially performed in 31 patients with hypopigmented bands
along Blaschko’s lines or segmental hypochromic patches, associated with
various extracutaneous features (flow diagram in Supplementary Figure 2).
We found a mosaic MTOR pathogenic variant in the skin from one patient
with hemimegalencephaly (HMEG) and severe epilepsy. Other patients
carried a mosaic chromosomal abnormality (7 cases), a germline X-linked
variant in TFE312,13 (1 case), a postzygotic variant in RHOA14 (2 cases) or
other candidate genes (4 cases), or remained negative (16 cases). Targeted
deep sequencing of MTOR was subsequently performed on hypopigmen-
ted skin and/or blood DNA from 40 additional patients with Blaschko-linear
hypopigmentation associated with epilepsy or intellectual deficiency who
were subsequently ascertained (Supplementary Figure 2).
Assessment of mTOR activation on cultured skin fibroblasts
Fibroblasts were obtained from a skin biopsy of patients P03 and P12. The
presence of c.4556C>T (p.[Ala1519Val]) and c.7255G>A (p.[Glu2419Lys])
substitutions was checked both by Sanger sequencing (ABI BigDye
Terminator Cycle Sequencing kit [v.3.1] and an ABI 3130 Genetic
Analyzer, Applied Biosystems, Villebon-sur-Yvette, France), and TUDS,
which allowed determination of variant allele fractions (VAFs). A mixed
culture of nonmutant and MTOR mutant skin fibroblasts (p.[Glu2419Lys],
VAF= 40%), three wild-type control fibroblast cultures (C1, C2, C3),
and mixed cultures of nonmutant and PIK3CA-mutant control fibroblasts
(p.[Gly1049Arg], VAF= 40%), M098 (p.[Gly418Lys], VAF= 32%), M018
(p.[Gln546Lys], VAF= 40%), and M032 (p.[His1047Arg], VAF= 30%) were
studied. Cells were maintained at 37 °C in a humidified incubator in DMEM
supplemented with 10% FBS, 1,000 u/l penicillin, 0.1 g/l streptomycin,
and 2mmol/l L-glutamine. Amino acid deprivation procedures were
conducted as previously described.15,16
Phosphorylation of AKT at residue 473 was assessed using a direct
enzyme-linked immunosorbent assay (ELISA) kit (InstantOne®, eBioscience,
Cambridge, UK, #85-86042-253). Results were expressed relative to control
levels and pooled; statistical analysis was performed using one-way
analysis of variance (ANOVA) with Tukey’s post hoc analyses. Phosphoryla-
tion of p70S6K at residue 389 was assessed by immunoblotting and
antibody labeling by Calnexin (#2679) and p70S6Kthr389 (#9234, Cell
Signalling Technology, London, UK). Cell size was measured on 10,000 cells
per run on an MS3 multisizer (Beckmann-Coulter), after incubation of
fibroblasts with or without amino acids, since phosphorylation of the PI3K-
AKT-MTOR pathway depends on nutrients.
Microscopy
Additional skin biopsies for optical and electron microscopy were obtained
from patients in each center and standard FFPE skin sections were
processed prior to centralized analysis. Immunoperoxidase staining was
performed on FFPE sections from P12 (hypopigmented and normal skin),
P05, and P06 (hypopigmented skin only) and two control FFPE sections
from age-matched controls, using anti-MITF (#NCL-L-MITF, 1:500, Leica,
Nanterre, France) and anti-Melan-A (1:200; ab731; Abcam, Cambridge, MA,
USA) mouse monoclonal antibodies. Glutaraldehyde-fixed skin biopsies
from P12 and P11 were prepared for electron microscopy following
standard procedures. Ultrathin sections (120 nm thick) were observed on a
JEOL JEM-1011 transmission electron microscope (JEOL, Croissy, France)
operating at 100 kV and pictures taken using ES1000W Erlangshen CCD
camera (GATAN, Elancourt, France). Stage I and stage IV melanosomes
were counted in 15 melanocytes from biopsies taken from both normal
(control) and hypomelanotic skin from patients P12 and P11, respectively.
Melanosomes were counted in 50 basal layer keratinocytes for each
sample. Statistical significance of differences was assessed using Wilcoxon
rank sum test, with a p value < 0.05 considered significant.
RESULTS
In one affected individual from the initial cohort of 31 patients
(P12), exome sequencing on DNA from hypopigmented skin
identified a de novo predicted missense p.(Glu2419Lys)
(c.7255G>A) MTOR variant, present in 21 of 74 reads (28%),
absent from blood-derived DNA from her unaffected parents
(Supplementary Table 2). The variant was absent from the
gnomAD variant database, found to affect a highly conserved
nucleotide and amino acid, and was predicted as likely
deleterious in silico. TUDS of the MTOR kinase domain harboring
the c.7255G>A substitution confirmed its presence in 29% of
alleles in whole skin biopsy, and 41% of alleles in cultured skin
fibroblasts. The variant was nearly undetectable in blood (less
than 1% of reads) (Fig. 1).
In the second cohort of 40 patients, this variation and ten
additional postzygotic MTOR substitutions were identified in
14 unrelated patients (35.0%): p.(Lys1452Asn), p.(Cys1483Tyr),
p.(Ala1519Val), p.(Ala1519Thr), p.(Glu1799Lys), p.(Thr1977Ile),
p.(Ile2017Thr), p.(Ser2413Ile), p.(Leu2427Pro), and p.(Ile2501Phe).
Hypomelanotic skin samples were available for further study in 13/
15 individuals with mosaic MTOR variants, and normally pigmen-
ted skin DNA was also available in one patient (P02). Skin VAFs
varied between 10% and 40% (median = 21%). Blood samples
were available in 12/15 individuals. MTOR variants were found in
blood in 6/12 patients, with lower VAFs than in the skin, between
1% and 30% (median= 0%) (Fig. 1, Supplementary Table 3).
Recurrent MTOR hotspots were identified in nine patients:
p.(Glu1799Lys), p.(Glu2419Lys), and p.(Ala1519Thr)/p.(Ala1519Val)
in two patients, as well as p.(Thr1977Ile) in three patients. Overall,
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five variants (p.[Lys1452Asn], p.[Ala1519Thr], p.[Ala1519Val], p.
[Ile2017Thr], p.[Ser2413Ile]) had never been reported previously.
Both p.(Glu2419Lys) and p.(Ile2017Thr) MTOR variants were
previously found to result in constitutive mTOR complex 1 (mTORC1)
activity in vitro and in vivo.17,18 Primary skin fibroblasts from P12,
with a VAF of 40%, were used to test p.(Glu2419Lys] mTOR activity
by assessing AKT and p70 ribosomal protein S6 kinase (p70S6K)
phosphorylation status15,19 (Supplementary Figure 3). ELISA (Sup-
plementary Figure 3a) and immunoblotting experiments (Supple-
mentary Figure 3b) following amino acid deprivation showed
increased levels of phosphorylated AKTser473 and p70S6Kthr389 in
mutant cells compared with controls. AKTser473 and p70S6Kthr389
phosphorylation levels were similar to those of skin fibroblasts
harboring PIK3CA activating variants (Supplementary Figure 3).
However, in amino acid–rich conditions, the p.(Glu2419Lys) MTOR
mutant cells showed no constitutive activity, in contrast with PIK3CA
mutant cell lines (Supplementary Figure 3c). We found no significant
differences in median cell diameter between mutant and control
cells (Supplementary Figure 3d). In comparison, in primary cultured
fibroblasts harboring the p.(Ala1519Val) MTOR variant at very low
levels (<1%), phosphorylation was not increased at baseline or
under amino acid deprivation.
The 15 patients (10 females and 5 males) aged 1–30 years
(median: 6 years), consisted of 13 children aged 14 or younger
and two adults. Fourteen patients had either well-limited or
ill-defined linear hypopigmentation along Blaschko’s lines, in a
typical S-shaped, V-shaped or whorled pattern, more visible
under Wood’s light, mainly located on the trunk and lower
limbs, without lateral predominance (Fig. 2, Supplementary
Table 4). One additional patient did not have linear hypomela-
nosis, but instead a hypopigmented patch of scalp hair, a
segmental cutaneous flag-like hypopigmented patch on his
shoulder, and iris heterochromia. Woolly/curly hair was found in
four patients, but no other anomalies of the integument or
mucous membranes were noted. Since a decrease in melano-
cyte numbers and melanosome maturation has been reported in
ash-leaf macules of tuberous sclerosis patients harboring loss-of-
function variants in TSC1 or TSC2, which encode upstream
inhibitors of mTOR, we studied melanogenesis in patients with
MTOR-related HI. Biopsies from hypomelanotic and normally
pigmented skin in patients P05, P06, P11, and P12, showed
fewer normal melanocytes per standardized field on Melan-A
immunostaining compared with controls (mean= 15.8 melano-
cytes/field for control skins and mean= 5.2 melanocytes/field in
HI skins, p= 2.6.10−9) (Fig. 3). On hypomelanotic skin biopsies,
MITF expression appeared normal, since anti-MITF labeling in
epidermal melanocytes was unchanged (Fig. 3). MITF labeling
was either positive (P12) or absent (P05 and P06). We failed to
identify downregulation of MITF in primary skin fibroblasts from
one patient (data not shown).
In patients P12 and P11, the number of stage IV melanosomes
were markedly decreased in 15 melanocytes from hypomelanotic
skin (n= 378 and n= 282, respectively), compared with 15
melanocytes from normal skin (n= 577 and n= 362, respectively)
(p= 0.03 for P12 and p= 0.0002 for P11) (Fig. 4). Likewise, the
stage IV/stage I melanosome ratio in melanocytes from hypome-
lanotic skin was reduced by 61.9% compared with normal skin in
patient P12, and by 87.3% in patient P11. Mean numbers of
melanosomes per cell were also decreased in keratinocytes from
hypomelanotic skin as compared with normal skin: by 75.0% in
patient P12, and by 67.6% in patient P11 (p value= 8.2.10−16 and
3.8.10−15 for P12 and P11).
Twelve patients had psychomotor impairment ranging from
mild (first steps achieved at 20 months) to severe (sitting position
achieved at 6 years). All of them subsequently had intellectual
disability (ID). Autism spectrum disorder was present in four
patients, who also had ID. Eight patients had macrocephaly
(occipitofrontal circumference [OFC] ≥+3 SD), associated with
unilateral body overgrowth in four of them. One patient had
slightly elevated OFC (+2.5 SD). Six patients had normal OFC, one
of them with hemihypertrophy, (Fig. 5, Supplementary Table 4).
Seizures were diagnosed in ten patients, including two without ID
(Fig. 5, Supplementary Table 4). Among patients with seizures,
only five had macrocephaly, whereas all five patients without
epilepsy had macrocephaly.
Brain MRI was performed in ten patients: three with normal OFC
and seven with macrocephaly. Among patients with macroce-
phaly, MRI showed normal symmetric brains without megalence-
phaly (MEG) (normal lateral ventricles and pericerebral spaces) in
four (Supplementary Table 4, Fig. 2). Among the ten patients who
had seizures, MRI was performed in six and showed HMEG in all of
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Fig. 1 Distribution of postzygotic missense MTOR variations. (a) Structure of mTOR protein including the Huntingtin, Elongation factor 3,
protein phosphatase 2A, and TOR1 (HEAT) repeat; FAT (FRAP, ATM, and TRRAP) domain; FRB (FKBP12-rapamycin binding) domain; kinase
(serine-threonine kinase kinase) domain; FATC (FAT, FRAP, ATM and TRRAP carboxy-terminal) domain; and FIT (Found in TOR) domain. Variant
allele fractions (VAFs) (%) are shown as pie charts with a maximum allele fraction of 50%. B (red) blood, DS dark skin, LS light skin. Variation
details are summarized in Supplementary Table 3. (b) Distribution of VAFs in hypopigmented skin (LS, black dots) and blood (red dots), with
median values.
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macrocephaly (OFC between +3 and +4 SD, in the three others).
All six cases of HMEG were characterized on MRI by (1) increased
volume of the white matter; (2) absence of signal change, except
in one case with bilateral frontal gray matter heterotopia; and (3)
cortex thickening in two patients. HMEG was also associated with
homolateral (four patients) or bilateral (one patient) narrowing of
lateral ventricle frontal horns, homolateral enlargement of the
thalamus and caudate nucleus (one patient), or homolateral
enlargement of cerebellum hemispheres (four patients). In the five
patients without epilepsy, MRI was performed in four and showed
either (2 cases) or normal brain (2 cases). Overall, 12 patients in
our series (80%) had either macrocephaly or HMEG/MEG.
Facial dysmorphism (Fig. 5, Supplementary Table 4) consisted of
hypertelorism, prominent forehead, depressed nasal bridge, or
downslanting palpebral fissures. In addition to iris heterochromia
in two cases, ocular involvement consisted of strabismus/
amblyopia, astigmatism, myopia, hypermetropia, coloboma, or
retinitis pigmentosa. Renal anomalies usually found in tuberous
sclerosis complex (TSC) (angiomyolipomas and renal cysts) were
absent in patients with mosaic MTOR pathogenic variants. On
ultrasonography, 2/12 patients had increased renal cortex
echogenicity, a nonspecific finding.
DISCUSSION
In this group of 71 patients with patterned dyspigmentation, we
identified a subset due to mosaicism for MTOR pathogenic
variants. We have further delineated the clinical spectrum of
MTOR-related HI with neurodevelopmental anomalies (Supple-
mentary Table 4). These features include ID, macrocephaly, HMEG,
and epilepsy, in addition to a pigmentation pattern suggestive of
mosaicism. This combination of neurocutaneous features has
previously been reported (Supplementary Table 5) in seven
patients with postzygotic MTOR activating pathogenic variants
(Supplementary Table 1). Two reported siblings with a germline
MTOR activating variant had a pigmentary phenotype without
further description.20
The severity of neurodevelopmental phenotypes varied greatly
among our patients. Intellectual functioning ranged from normal
to severe ID. Patients without ID had epilepsy or MEG. This
neurodevelopmental spectrum overlaps with Smith–Kingsmore
syndrome (SKS), caused either by germline MTOR pathogenic
variants, or mosaic MTOR pathogenic variants with high VAFs in
the brain.20 Presence of HI, absent in SKS patients with a
constitutional heterozygous MTOR pathogenic variant, may be
an indication of mosaicism and the need for further studies. To
date, ID has been reported in all patients with SKS or postzygotic
MTOR pathogenic variants and HMEG. Severe ID was present in
patient P15, who harbored a postzygotic p.(Ile2501Phe) change. In
contrast, two individuals from one previously published family,
who carried a germline p.(Ile2501Val) variant, had normal
cognition, focal epilepsy, and normal OFC.21 Since discrepancies
in the cerebral phenotype for an identical germline variant cannot
be explained by different amounts of mutant brain cells, the very
mild phenotype in this family would be better explained by a
milder gain-of-function effect of the p.(Ile2501Val) substitution
than of the p.(Ile2501Phe) substitution that we found in a mosaic
state in our patient.
MRI showed HMEG in all six cases with seizures, whereas in four
patients without epilepsy, MRI showed either MEG or a normal
brain. This suggests that, in patients with postzygotic MTOR
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Fig. 2 Clinical pigmentary skin phenotype and brain imaging. Clinical pigmentary skin phenotype in two patients (Left). (a, b) P11. (a)
Unilateral linear and whorled hypopigmentation in multiple large bands with ragged border and sharp midline limitation on the abdomen. (b)
Enhanced contrast on Wood’s lamp illumination. (c, d) P12. (c) Linear hypopigmentation in large bands on left lower limb. (d) Enhanced
contrast on Wood’s lamp illumination. (e, f) Facial features of patients P09 and P11. Brain magnetic resonance image (MRI) of subjects P01, P03,
P10 and P12 (Right). (a–c) P12. Left HMEG with altered ventricle shape (small frontal horn), enlarged left thalamus and caudate nucleus (a),
slightly thickened cortical mantle and enlarged white matter with normal signal (b) and enlarged anterior corpus callosum (c). (d–f) P03.
Normal corpus callosum (d), small frontal horns (e, f), and mild overgrowth of the right cerebral hemisphere, with slight enlargement of the
right posterior ventricle (c). (g–i) P10. Normal corpus callosum on sagittal section (g), overgrowth of the right cerebellar hemisphere (h), right
posterior ventricle enlargement, small frontal horn, increased white matter volume and thickened cortical mantle (i). (j–l) P01. Thickened
corpus callosum (j), with symmetrical enlargement of cerebellar (k) and cerebral hemispheres (l).
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MEG. MRI did not show cortical or other cerebral malformations in
the two MEG patients and in three of the HMEG patients, while
only three patients with HMEG had focal cortex thickening
suggestive of polymicrogyria or periventricular heterotopia.
Hence, our series also supports that, in patients with a
neurodevelopmental phenotype, HMEG or MEG without apparent
brain malformation might be more suggestive of pathogenic
variants in MTOR rather than in PIK3CA or AKT3, as previously
outlined.22–25 Interestingly, the structure and function of homo-
geneously enlarged brains with postzygotic MTOR pathogenic
variants may be less altered than of those with HMEG. Indeed,
previous studies comparing phenotypes related to either post-
zygotic or germline MTOR pathogenic variants have suggested
that severity of neurodevelopmental impairment does not
correlate with the proportion of affected brain cells.20,21,25 This is
likely explained by increased strength of the gain-of-function
effect of mosaic pathogenic variants, which would result in
embryonic lethality in the germline state, compared with a milder
effect of germline pathogenic variants, which would be compa-
tible with fetus survival.
A pigmentary phenotype with hypopigmentation and hyper-
pigmentation has previously been reported in one of two sibs who
both harbored a germline p.(Phe2202Cys) MTOR variant,20 but its
precise clinical description is missing, and no conclusions can be
drawn from this case about the role of germline MTOR pathogenic
variants on skin pigmentation. All patients in our series carried
postzygotic MTOR pathogenic variants in their skin, which were
absent from blood in 50% of cases tested. Linear hypopigmenta-
tion has been considered a nonspecific manifestation of mosai-
cism, as various types of nonrecurrent chromosome anomalies
were initially reported in association with the phenotype, and
some authors have even suggested that the term “hypomelanosis
of Ito” should be abandoned.11 However, we and others have now
found mosaic single-gene defects in HI, such as MTOR or RHOA
pathogenic variants.14 In one case of the phenotypic “opposite” of
HI, linear and whorled nevoid hypermelanosis,26 where Blaschko-
linear hyperpigmentation is the cardinal cutaneous feature, we
have also described a pathogenic mosaic variant in the KITLG
gene.27 Hence, hypo/hyperpigmentation along Blaschko’s lines





























Fig. 3 Microscopy of paraffin embedded skin biopsies. (a) Numbers of melanocytes per field on whole skin sections from patients P05, P06,
and P12 (patients: 6 fields; controls: 13 and 24 fields; hematoxylin eosin [HE] staining). DS dark skin, LS light skin. (b) HE staining from P06
hypomelanotic skin. (c) Subject P12. Melan-A immunohistochemistry on skin biopsy sections from pigmented skin (top) and hypomelanotic
skin (bottom). (d) Subject P12. MITF labeling on biopsy sections from pigmented skin (top) and hypomelanotic skin (bottom). Scale bar:
100 µm. Melanocytes are shown by arrowheads.
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somatic mosaicism, since, in combination with extracutaneous
findings, it may also specifically point at the causative gene.
The MTOR gene encodes the mechanistic target of rapamycin
(mTOR). This serine-threonine kinase is highly conserved, and is an
essential component of MTORC1 and MTORC2 complexes. The
PI3K-AKT-mTOR signaling pathway is pivotal in cell growth,
protein synthesis, autophagy, and cytoskeletal dynamics.28–30
Although MITF labeling studies were inconclusive, cutaneous
hypopigmentation may directly result from mTOR complex
hyperactivation. In TSC, a condition resulting from loss of function
of TSC1 or TSC2,31 activation of mTOR has been shown to suppress
melanogenesis via MITF downregulation, resulting in typical ash-
leaf or confetti-like hypopigmented macules.32–34 Repigmentation
can be obtained by treatment with topical mTOR inhibitor
rapamycin,35 since mTORC1 inhibition results in induction of
melanogenesis through upregulation of MITF and its downstream
targets TRP1 and TRP2.32,33,36,37 In hypopigmented skin of four
patients with MTOR-related HI, we found a decrease in melano-
cytes, a defect in the maturation process of melanosomes, and a
reduced number of melanosomes in keratinocytes, as well as
activating MTOR variants and increased AKT and p70S6K
phosphorylation in dermal fibroblasts from patients. Our findings
are consistent with upregulation of mTORC1 resulting in partial
suppression of melanogenesis. Paradoxically though, in P02,
normally pigmented skin harbored a VAF of 25%, whereas the
VAF was only 10% in hypopigmented skin. We hypothesize that
lower VAFs may result from death of mutant cells in hypopig-
mented areas through autophagy, as recently shown in TSC.33 A
decreased number of melanocytes was found both in hypopig-
mented and normal skin in P12 (Fig. 3), which supports this
hypothesis.
Our results highlight the diagnostic importance of accurate
clinical phenotyping of mosaic syndromes, and provide further
evidence that genetic defects underlying HI extend beyond
chromosomal mosaicism. Additional genetic defects remain to be
identified in a number of patients with linear hypopigmentation
and various associated manifestations. Yet, identification of
mosaic MTOR pathogenic variants in HI with neurodevelopmental
defects defines a clinically and genetically recognizable condition.
It has direct clinical implications for genetic tests and genetic
counseling.
Most MTOR pathogenic variants, not found in the germline
state, are thought to be embryonic lethal. Hence, the risk of
transmission from a mosaic patient harboring this type of variant
appears low or absent. However, transmission of nonlethal
pathogenic variants, resulting in offspring with SKS, is still possible.
Although the positive predictive value of HI with neurodevelop-
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Fig. 4 Ultrastructural study. (a) Melanosome maturation in melanocytes: Melanosome count in melanocytes on skin biopsy sections from
pigmented (black) and hypopigmented area (white) in patients P12 (left) and P11 (right). Melanosomes were counted in 15 melanocytes.
Upper bars: stage I melanosome. Lower bars: stage IV melanosomes (numbers at top of each bar). Ratio and total number of counted
melanosomes are given at top and bottom of each figure. (b) Melanosome quantification in keratinocytes. Mean number of melanosomes per
basal layer keratinocyte (n= 50) (c). Transmission electron microscopy (TEM) of melanocytes at the basal epidermal layer in subjects P12 (a, b)















































































































































































Fig. 5 Clinical features in hypomelanosis of Ito (HI) individuals with MTOR postzygotic pathogenic variants. (a) Frequencies of
neurological involvement and overgrowth. (b) Standard deviations for occipitofrontal circumference (OFC) (dark gray) and body height (light
gray). (c) Frequencies of recurrent facial features. Percentages were calculated with the number of patients with available data as the
denominator. ID intellectual disability, MI mild, MO moderate, S severe.
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not yet known, in our series, MTOR pathogenic variants were
found in more than one third (36.6%) of patients with HI and
seizures. Likewise, macrocephaly and/or HMEG/MEG, found in 80%
of cases in our series, appear as fairly specific, as they were absent
from patients with mosaic RHOA pathogenic variants.14,38 Hence,
in our opinion, such typical clinical presentation warrants MTOR
sequencing by ultrasensitive methods. DNA from the skin or other
affected tissue is required for genetic testing, since the VAF is
higher in skin (21%) compared with blood (0%), where MTOR
pathogenic variants are usually absent or at very low levels, close
to next-generation sequencing detection limit (1% at a depth of
1,000×). Last, clinical consequences of mTORC1 upregulation,
particularly neurological involvement, may be amenable to
tailored treatment with mTOR inhibitors, although data on efficacy
are inconclusive so far.39
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